Terms: = Uterine cancer AND Neurokinin
12 results:
1. neurokinin-1 receptor is highly expressed in cervical cancer and its antagonist induces cervical cancer cell apoptosis.
Guan L; Yuan S; Ma J; Liu H; Huang L; Zhang F
Eur J Histochem; 2023 Jan; 67(1):. PubMed ID: 36629320
[TBL] [Abstract] [Full Text] [Related]
2. Control and Risk Factors of Nausea and Vomiting in Patients With Cervical cancer Receiving Radiotherapy.
Uno A; Yamamoto S; Iihara H; Fujii H; Makita C; Hayasaki Y; Ueda Y; Ito M; Takenaka M; Kumano T; Mori M; Yasue M; Kato-Hayashi H; Kobayashi R; Morishige KI; Matsuo M; Hayashi H; Suzuki A
Anticancer Res; 2022 Jun; 42(6):3117-3123. PubMed ID: 35641271
[TBL] [Abstract] [Full Text] [Related]
3. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in endometrial cancer.
Gharaee N; Pourali L; Jafarian AH; Hashemy SI
Mol Biol Rep; 2018 Dec; 45(6):2257-2262. PubMed ID: 30225581
[TBL] [Abstract] [Full Text] [Related]
5. Investigational and experimental GnRH analogs and associated neurotransmitters.
Blumenfeld Z
Expert Opin Investig Drugs; 2017 Jun; 26(6):661-667. PubMed ID: 28441891
[TBL] [Abstract] [Full Text] [Related]
6. Altered expression of the tachykinins substance P/neurokinin A/hemokinin-1 and their preferred neurokinin 1/neurokinin 2 receptors in uterine leiomyomata.
González-Santana A; Marrero-Hernández S; Dorta I; Hernández M; Pinto FM; Báez D; Bello AR; Candenas L; Almeida TA
Fertil Steril; 2016 Nov; 106(6):1521-1529. PubMed ID: 27456549
[TBL] [Abstract] [Full Text] [Related]
7. Substance P Promotes the Progression of Endometrial Adenocarcinoma.
Ma J; Yuan S; Cheng J; Kang S; Zhao W; Zhang J
Int J Gynecol Cancer; 2016 Jun; 26(5):845-50. PubMed ID: 27051050
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Ruhlmann CH; Christensen TB; Dohn LH; Paludan M; Rønnengart E; Halekoh U; Hilpert F; Feyer P; Kristensen G; Hansen O; Keefe D; Herrstedt J
Lancet Oncol; 2016 Apr; 17(4):509-518. PubMed ID: 26952945
[TBL] [Abstract] [Full Text] [Related]
9. Therapeutic Neuroendocrine Agonist and Antagonist Analogs of Hypothalamic Neuropeptides as Modulators of the Hypothalamic-Pituitary-Gonadal Axis.
Newton CL; Anderson RC; Millar RP
Endocr Dev; 2016; 30():106-29. PubMed ID: 26684214
[TBL] [Abstract] [Full Text] [Related]
10. Addition of the neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Jahn F; Riesner A; Jahn P; Sieker F; Vordermark D; Jordan K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1101-1107. PubMed ID: 26059352
[TBL] [Abstract] [Full Text] [Related]
11. Neuromedin U: a multifunctional neuropeptide with pleiotropic roles.
Martinez VG; O'Driscoll L
Clin Chem; 2015 Mar; 61(3):471-82. PubMed ID: 25605682
[TBL] [Abstract] [Full Text] [Related]
12. Current and future applications of GnRH, kisspeptin and neurokinin B analogues.
Millar RP; Newton CL
Nat Rev Endocrinol; 2013 Aug; 9(8):451-66. PubMed ID: 23817290
[TBL] [Abstract] [Full Text] [Related]
